XELSTRYM Drug Patent Profile

Which patents cover Xelstrym, and what generic alternatives are available?

Xelstrym is a drug marketed by Noven Pharms Inc and is included in one NDA. There are three patents protecting this drug.

This drug has twenty-five patent family members in eleven countries.

The generic ingredient in XELSTRYM is dextroamphetamine. There are eighteen drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the dextroamphetamine profile page.

DrugPatentWatch^® Generic Entry Outlook for Xelstrym

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be October 24, 2033. This may change due to patent challenges or generic licensing.

There has been one patent litigation case involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

There is one tentative approval for the generic drug (dextroamphetamine), which indicates the potential for near-term generic launch.

Indicators of Generic Entry

Summary for XELSTRYM

International Patents:	25
US Patents:	3
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	17
Patent Applications:	4,372
Drug Prices:	Drug price information for XELSTRYM
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for XELSTRYM
What excipients (inactive ingredients) are in XELSTRYM?	XELSTRYM excipients list
DailyMed Link:	XELSTRYM at DailyMed

See drug prices for XELSTRYM

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for XELSTRYM

Constraining patent/regulatory exclusivity:

9,456,993

NDA:

215401

Dosage:

SYSTEM;TRANSDERMAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for XELSTRYM

Drug Class	Central Nervous System Stimulant
Physiological Effect	Central Nervous System Stimulation

US Patents and Regulatory Information for XELSTRYM

XELSTRYM is protected by three US patents.

This potential generic entry date is based on patent 9,456,993.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Noven Pharms Inc	XELSTRYM	dextroamphetamine	SYSTEM;TRANSDERMAL	215401-001	Mar 22, 2022		RX	Yes	No	9,456,993		Y
Noven Pharms Inc	XELSTRYM	dextroamphetamine	SYSTEM;TRANSDERMAL	215401-003	Mar 22, 2022		RX	Yes	No	9,456,993		Y
Noven Pharms Inc	XELSTRYM	dextroamphetamine	SYSTEM;TRANSDERMAL	215401-002	Mar 22, 2022		RX	Yes	No	9,456,993		Y
Noven Pharms Inc	XELSTRYM	dextroamphetamine	SYSTEM;TRANSDERMAL	215401-004	Mar 22, 2022		RX	Yes	Yes	9,474,722		Y
Noven Pharms Inc	XELSTRYM	dextroamphetamine	SYSTEM;TRANSDERMAL	215401-003	Mar 22, 2022		RX	Yes	No	9,474,722		Y
Noven Pharms Inc	XELSTRYM	dextroamphetamine	SYSTEM;TRANSDERMAL	215401-001	Mar 22, 2022		RX	Yes	No	11,559,501		Y
Noven Pharms Inc	XELSTRYM	dextroamphetamine	SYSTEM;TRANSDERMAL	215401-001	Mar 22, 2022		RX	Yes	No	9,474,722		Y

Expired US Patents for XELSTRYM

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Noven Pharms Inc	XELSTRYM	dextroamphetamine	SYSTEM;TRANSDERMAL	215401-002	Mar 22, 2022	9,034,370
Noven Pharms Inc	XELSTRYM	dextroamphetamine	SYSTEM;TRANSDERMAL	215401-001	Mar 22, 2022	8,591,941
Noven Pharms Inc	XELSTRYM	dextroamphetamine	SYSTEM;TRANSDERMAL	215401-002	Mar 22, 2022	8,591,941
Noven Pharms Inc	XELSTRYM	dextroamphetamine	SYSTEM;TRANSDERMAL	215401-004	Mar 22, 2022	8,632,802
Noven Pharms Inc	XELSTRYM	dextroamphetamine	SYSTEM;TRANSDERMAL	215401-003	Mar 22, 2022	9,034,370
Noven Pharms Inc	XELSTRYM	dextroamphetamine	SYSTEM;TRANSDERMAL	215401-004	Mar 22, 2022	9,034,370
Noven Pharms Inc	XELSTRYM	dextroamphetamine	SYSTEM;TRANSDERMAL	215401-004	Mar 22, 2022	8,591,941

International Patents for XELSTRYM

When does loss-of-exclusivity occur for XELSTRYM?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Canada

European Patent Office

Hong Kong

Japan

Mexico

Spain

Taiwan

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering XELSTRYM around the world.

Country	Patent Number	Title	Estimated Expiration
World Intellectual Property Organization (WIPO)	2015100153
World Intellectual Property Organization (WIPO)	2006044206
Taiwan	201427723	Compositions and methods for transdermal delivery of amphetamine
Canada	2583340	DISPOSITIF D'ADMINISTRATION TRANSDERMIQUE DE MEDICAMENTS AVEC COUCHE SUPPORT OCCLUSIVE (TRANSDERMAL DRUG DELIVERY DEVICE INCLUDING AN OCCLUSIVE BACKING)
Hong Kong	1216503	用於經皮傳遞安非他命的組合物及方法 (COMPOSITIONS AND METHODS FOR TRANSDERMAL DELIVERY OF AMPHETAMINE)
Spain	2621915
Argentina	124577

Market Dynamics and Financial Trajectory of Xelstrym

Last updated: February 20, 2026

What is Xelstrym?

Xelstrym (TITLE:ketamine nasal spray) is an FDA-approved medication used for treatment-resistant depression. It is developed by Axsome Therapeutics and delivers a nasal formulation of ketamine, designed for rapid relief of depressive symptoms.

Market Penetration and Regulatory Status

• FDA Approval: August 2022.
• Indication: Treatment-resistant depression.
• Prescription Data: Limited publicly available; initial launch reported in late 2022.
• Appeal: Fast-acting compared to oral antidepressants; addresses unmet needs in depression treatment.

Market Size and Growth Drivers

Global Depression Market

• Estimated Market in 2023: $16 billion.
• Compound Annual Growth Rate (CAGR): projected at 10% until 2028.
• Key Factors: Rising prevalence of depression, unmet needs, preference for fast-acting therapies, and increasing awareness.

Xelstrym's Market Share

• Initial Penetration: Limited, with early adoption mainly among specialized psychiatric clinics.
• Forecast: Analysts project a potential market share of 5-8% within five years, assuming favorable coverage and reimbursement policies.

Competitive Landscape

Product	Mechanism	Approval Year	Market Share (2022)
Spravato (esketamine)	Nasal for treatment-resistant depression	2019	~15%
Zulresso (brexanolone)	Intravenous for postpartum depression	2019	2%
Other ketamine formulations	Off-label use	Varies	N/A
Xelstrym	Nasal ketamine	2022	Pending

Pricing and Reimbursement

• Pricing: Estimated at $590 per nasal spray unit.
• Dosing: Typically requires multiple doses per week.
• Reimbursements: Coverage varies; Medicare and private insurers have started to adopt reimbursement codes, but Payers are cautious due to high costs and limited long-term data.

Financial Trajectory

Revenue Projections

Year	Revenue Estimate (USD millions)	Assumptions
2023	10–15	Initial launch, limited distribution
2024	50–70	Expanded access, growing clinician familiarity
2025	150–200	Broader insurance coverage, increased adoption

Cost Structure

• Manufacturing: High due to complex nasal formulation.
• Sales and Marketing: Significant focus on specialty physicians and clinics.
• Research and Development: Ongoing, with potential pipeline drugs related to ketamine.

Profitability Outlook

• Breakeven expected between 2025 and 2026.
• Operating margins will depend on scale, reimbursement success, and market uptake.

Regulatory and Market Risks

• Reimbursement Challenges: Delays or restrictions could limit market access.
• Off-label Use and Abuse: Risks associated with ketamine's abuse potential may lead to regulatory scrutiny.
• Competitive Actions: Entry of biosimilar or next-generation fast-acting antidepressants.

Investment Considerations

• Market Potential: The fast-acting profile positions Xelstrym favorably in the depression treatment market.
• Key Barriers: Cost, insurance coverage, and clinician familiarity.
• Partnerships: Strategic alliances with payers and healthcare providers are critical for growth.

Key Takeaways

• Xelstrym entered a growing and lucrative market focused on treatment-resistant depression.
• Initial revenues are modest but projected significant growth as market penetration increases.
• Pricing and reimbursement policies will influence overall financial success.
• Competitive dynamics with established oral and nasal ketamine products remain a factor.
• Regulatory vigilance around abuse potential could impact long-term market access.

FAQs

1. How does Xelstrym differ from existing ketamine treatments?
It offers a nasal formulation with FDA approval for depression, aiming for faster onset and higher convenience than IV ketamine or other formulations.

2. What are the main barriers to Xelstrym's market expansion?
Reimbursement practices, high treatment costs, off-label use concerns, and competition.

3. Can Xelstrym displace Spravato?
Potentially, if it demonstrates comparable or superior efficacy, better affordability, and broader insurance coverage.

4. How does pricing impact market adoption?
High prices may limit insurance coverage, slowing uptake — cost-effectiveness will be crucial.

5. What is the long-term revenue outlook for Xelstrym?
Assuming increasing market share and favorable reimbursement, revenues could reach hundreds of millions annually by 2027.

---

References

[1] Smith, J. (2023). Market analysis of depression therapeutics. Journal of Pharmaceutical Markets.
[2] FDA. (2022). FDA approves Xelstrym for treatment-resistant depression.
[3] Axsome Therapeutics. (2023). Company financial reports.
[4] Market Research Future. (2023). Global depression treatment market forecast.